FLT3 and cancer: Although we cannot formally exclude that base editing could induce additional unpredicted on-target mutations, the regions affected by base editing are distant from mutational hotspots of cancer-associated variants (that is, the tyrosine kinase domain for KIT and FLT3 or the juxta-membrane domain for FLT3).